Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$8.52 -0.7%	$8.76	$6.01 ▼ $11.31	$1.79B	1.1	3.76 million shs	1.41 million shs
CLDX Celldex Therapeutics	$22.60 +3.9%	$22.19	$14.40 ▼ $47.00	$1.50B	1.22	992,865 shs	1.39 million shs
NVAX Novavax	$7.58 +1.1%	$7.33	$5.01 ▼ $15.22	$1.23B	2.5	6.80 million shs	12.15 million shs
VSTM Verastem	$9.29 +4.4%	$5.93	$2.34 ▼ $9.43	$571.75M	0.83	1.83 million shs	2.61 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	+2.26%	+3.62%	+0.35%	-18.75%	+4.25%
CLDX Celldex Therapeutics	-0.82%	-9.45%	-6.85%	+16.56%	-42.31%
NVAX Novavax	-0.27%	-21.22%	+0.40%	+8.38%	-34.84%
VSTM Verastem	-0.89%	+14.25%	+44.95%	+16.95%	+241.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCRX BioCryst Pharmaceuticals	4.1499 of 5 stars	3.5	2.0	4.2	2.5	2.5	0.6
CLDX Celldex Therapeutics	1.7239 of 5 stars	3.4	3.0	0.0	2.4	0.0	0.0
NVAX Novavax	4.5429 of 5 stars	3.1	2.0	4.7	2.5	0.8	3.1
VSTM Verastem	3.147 of 5 stars	3.5	3.0	0.0	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.90	Moderate Buy	$16.70	96.01% Upside
CLDX Celldex Therapeutics	2.78	Moderate Buy	$46.67	106.49% Upside
NVAX Novavax	2.13	Hold	$15.57	105.43% Upside
VSTM Verastem	3.00	Buy	$13.29	43.01% Upside

Current Analyst Ratings Breakdown

Latest VSTM, BCRX, CLDX, and NVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	VSTM Verastem	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/20/2025	CLDX Celldex Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$44.00 ➝ $38.00
8/20/2025	CLDX Celldex Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$56.00 ➝ $48.00
8/20/2025	CLDX Celldex Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $62.00
8/20/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $42.00
8/20/2025	NVAX Novavax	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform	$9.00 ➝ $7.00
8/12/2025	VSTM Verastem	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/8/2025	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$12.00 ➝ $13.00
8/4/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
7/22/2025	NVAX Novavax	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00
7/1/2025	BCRX BioCryst Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$450.71M	3.97	N/A	N/A	($2.01) per share	-4.24
CLDX Celldex Therapeutics	$7.02M	213.80	N/A	N/A	$9.87 per share	2.29
NVAX Novavax	$1.08B	1.14	N/A	N/A	$0.23 per share	32.96
VSTM Verastem	$2.14M	267.55	N/A	N/A	$0.59 per share	15.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.18	N/A	N/A	1.91	-6.41%	N/A	-1.78%	11/3/2025 (Estimated)
CLDX Celldex Therapeutics	-$157.86M	-$3.01	N/A	N/A	N/A	-3,446.88%	-27.61%	-26.20%	11/5/2025 (Estimated)
NVAX Novavax	-$187.50M	$2.28	3.32	94.75	0.10	39.20%	-142.33%	28.65%	11/11/2025 (Estimated)
VSTM Verastem	-$130.64M	-$3.28	N/A	N/A	N/A	N/A	-2,003.62%	-119.85%	11/5/2025 (Estimated)

Latest VSTM, BCRX, CLDX, and NVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	CLDX Celldex Therapeutics	-$0.86	-$0.85	+$0.01	-$0.85	$1.13 million	$0.73 million
8/7/2025	Q2 2025	VSTM Verastem	-$0.64	-$0.39	+$0.25	-$0.39	$6.01 million	$2.14 million
8/6/2025	Q2 2025	NVAX Novavax	-$0.07	$0.62	+$0.69	$0.62	$149.19 million	$239.24 million
8/4/2025	Q2 2025	BCRX BioCryst Pharmaceuticals	$0.03	$0.15	+$0.12	$0.02	$149.59 million	$163.35 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.25	2.22
CLDX Celldex Therapeutics	N/A	19.67	19.67
NVAX Novavax	5.93	2.36	2.34
VSTM Verastem	2.06	3.46	3.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
CLDX Celldex Therapeutics	N/A
NVAX Novavax	53.04%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	5.10%
CLDX Celldex Therapeutics	4.40%
NVAX Novavax	1.00%
VSTM Verastem	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	209.92 million	199.21 million	Optionable
CLDX Celldex Therapeutics	150	66.41 million	63.49 million	Optionable
NVAX Novavax	1,990	162.42 million	160.80 million	Optionable
VSTM Verastem	50	61.55 million	60.25 million	Optionable

VSTM, BCRX, CLDX, and NVAX Headlines

Recent News About These Companies

Verastem Oncology to Present at Upcoming Investor Conferences

August 27 at 7:11 AM | mms.businesswire.com

Verastem, Inc. $VSTM Shares Sold by Stonepine Capital Management LLC

August 26 at 7:38 AM | marketbeat.com

Verastem’s Promising Phase 3 Trial in Ovarian Cancer: A Potential Game-Changer?

August 25 at 12:50 PM | tipranks.com

Balyasny Asset Management L.P. Increases Stake in Verastem Inc

August 20, 2025 | gurufocus.com

Brokerages Set Verastem, Inc. (NASDAQ:VSTM) Price Target at $13.29

August 20, 2025 | americanbankingnews.com

Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Moderate Buy" from Analysts

August 18, 2025 | marketbeat.com

Zacks Research Upgrades Verastem (NASDAQ:VSTM) to "Hold"

August 17, 2025 | marketbeat.com

Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects

August 17, 2025 | insidermonkey.com

Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects

August 17, 2025 | finance.yahoo.com

Verastem price target lowered to $14 from $16 at Mizuho

August 15, 2025 | msn.com

Verastem stock soars after KRAS inhibitor shows strong lung cancer results

August 14, 2025 | za.investing.com

Verastem Unveils Promising VS-7375 Study Results

August 14, 2025 | msn.com

Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

August 13, 2025 | businesswire.com

Verastem Inc. Earnings Call: Positive Outlook with Key Achievements

August 13, 2025 | msn.com

Verastem, Inc. (NASDAQ:VSTM) Q2 2025 Earnings Call Transcript

August 12, 2025 | msn.com

Wall Street Zen Upgrades Verastem (NASDAQ:VSTM) to "Hold"

August 11, 2025 | marketbeat.com

Verastem (NASDAQ:VSTM) Releases Quarterly Earnings Results

August 10, 2025 | marketbeat.com

Verastem (NASDAQ:VSTM) Price Target Raised to $13.00

August 10, 2025 | marketbeat.com

Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Verastem, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 8, 2025 | seekingalpha.com

Verastem climbs on Q2 beat as new ovarian cancer drug boosts topline

August 8, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM, BCRX, CLDX, and NVAX Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.52 -0.06 (-0.70%)

Closing price 04:00 PM Eastern

Extended Trading

$8.59 +0.07 (+0.82%)

As of 04:54 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Celldex Therapeutics NASDAQ:CLDX

$22.60 +0.85 (+3.91%)

Closing price 04:00 PM Eastern

Extended Trading

$22.63 +0.03 (+0.13%)

As of 05:33 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Novavax NASDAQ:NVAX

$7.58 +0.08 (+1.07%)

Closing price 04:00 PM Eastern

Extended Trading

$7.64 +0.06 (+0.86%)

As of 05:55 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Verastem NASDAQ:VSTM

$9.29 +0.39 (+4.38%)

Closing price 04:00 PM Eastern

Extended Trading

$9.10 -0.18 (-1.99%)

As of 05:33 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time